A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (Pts) at High Risk for Recurrence
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p166
Full Text
Open PDFAbstract
Available in full text
Date
November 4, 2015
Authors
Publisher
BMJ